Process development for pandemic influenza VLP vaccine production using a baculovirus expression system

被引:35
作者
Lai, Chia-Chun [1 ,2 ]
Cheng, Yu-Chieh [1 ]
Chen, Pin-Wen [1 ]
Lin, Ting-Hui [1 ,2 ]
Tzeng, Tsai-Teng [1 ]
Lu, Chia-Chun [1 ]
Lee, Min-Shi [1 ]
Hu, Alan Yung-Chih [1 ]
机构
[1] NHRI, Natl Inst Infect Dis & Vaccinol, 35 Keyan Rd, Zhunan 35053, Miaoli County, Taiwan
[2] Natl Tsing Hua Univ, Coll Life Sci, 101,Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan
关键词
Influenza vaccines; Virus-like particle; Dissolved oxygen; VIRUS-LIKE PARTICLES; PROTECTIVE IMMUNITY; H7N9; INFLUENZA; GENERATION;
D O I
10.1186/s13036-019-0206-z
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background Influenza viruses cause hundreds of thousands of respiratory diseases worldwide each year, and vaccination is considered the most effective approach for preventing influenza annual epidemics or pandemics. Since 1950, chicken embryonated eggs have been used as the main method for producing seasonal influenza vaccines. However, this platform has the main drawback of a lack of scale-up flexibility, and thus, egg-based vaccine manufacturers cannot supply sufficient doses within a short period for use for pandemic prevention. As a result, strategies for reducing the manufacturing time and increasing production capacity are urgently needed. Non-virion vaccine methods have been considered an alternative strategy against an influenza pandemic, and the purpose of maintaining an immunogenic capsule structure with infectious properties appears to be met by the virus-like particle (VLP) platform. Results An influenza H7N9-TW VLP production platform using insect cells, which included the expression of hemagglutinin (HA), NA, and M1 proteins, was established. To scale up H7N9-TW VLP production, several culture conditions were optimized to obtain a higher production yield. A high level of dissolved oxygen (DO) could be critical to H7N9-TW VLP production. If the DO was maintained at a high level, the HA titer obtained in the spinner flask system with ventilation was similar to that obtained in a shake flask. In this study, the HA titer in a 5-L bioreactor with a well-controlled DO level was substantially improved by 128-fold (from 4 HA units (HAU)/50 mu L to 512 HAU/50 mu L). Conclusions In this study, a multigene expression platform and an effective upstream process were developed. Notably, a high H7N9-TW VLP yield was achieved using a two-step production strategy while a high DO level was maintained. The upstream process, which resulted in high VLP titers, could be further used for large-scale influenza VLP vaccine production.
引用
收藏
页数:9
相关论文
共 44 条
[1]  
[Anonymous], 2014, HUM VACC IMMUNOTHER, V10, P3103
[2]  
[Anonymous], 2017, CVPR, DOI DOI 10.1002/JCB.26286
[3]  
Bornstein J, 2010, THERAPY, V7, P75
[4]   Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin [J].
Bright, Rick A. ;
Carter, Donald M. ;
Daniluk, Shannon ;
Toapanta, Franklin R. ;
Ahmad, Attiya ;
Gavrilov, Victor ;
Massare, Mike ;
Pushko, Peter ;
Mytle, Nutan ;
Rowe, Thomas ;
Smith, Gale ;
Ross, Ted M. .
VACCINE, 2007, 25 (19) :3871-3878
[5]  
Casal J I, 2001, Biotechnol Genet Eng Rev, V18, P73
[6]   The first case of H7N9 influenza in Taiwan [J].
Chang, Sui-Yuan ;
Lin, Pi-Han ;
Tsai, Jen-Chih ;
Hung, Chien-Ching ;
Chang, Shan-Chwen .
LANCET, 2013, 381 (9878) :1621-1621
[7]   Evaluation of MDCK Cell-Derived Influenza H7N9 Vaccine Candidates in Ferrets [J].
Chia, Min-Yuan ;
Hu, Alan Yung-Chih ;
Tseng, Yu-Fen ;
Weng, Tsai-Chuan ;
Lai, Chia-Chun ;
Lin, Jun-Yang ;
Chen, Po-Ling ;
Wang, Ya-Fang ;
Chao, Sin-Ru ;
Chang, Jui-Yuan ;
Hwang, Yi-Shiuh ;
Yeh, Chia-Tsui ;
Yu, Cheng-Ping ;
Chen, Yee-Chun ;
Su, Ih-Jen ;
Lee, Min-Shi .
PLOS ONE, 2015, 10 (03)
[8]   Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield [J].
Chung, Cheng-Yu ;
Chen, Chi-Yuan ;
Lin, Shih-Yeh ;
Chung, Yao-Chi ;
Chiu, Hsin-Yi ;
Chi, Wei-Kuang ;
Lin, Yu-Li ;
Chiang, Bor-Luen ;
Chen, Wei-Jheng ;
Hu, Yu-Chen .
VACCINE, 2010, 28 (43) :6951-6957
[9]  
Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595
[10]  
Cox MMJ, 2008, INFLUENZA OTHER RESP, V2, P211, DOI 10.1111/j.1750-2659.2008.00053.x